REGULATORY

• New Govt Forum to Compile Interim Report to Create Innovation Ecosystem
  March 8, 2024

• COVID Vaccine Labels to Be Updated with Booster Use as Main Regimen
  March 8, 2024

• Japan Cabinet OKs Bill to Amend Regenerative Medicine Safety Act, Clinical Trial Act
  March 7, 2024

• New Govt Forum for Fighting Drug Loss Should Devise Strategies for Honebuto: LDP Members
  March 6, 2024

• Xocova Approval Meaningful, but Careful Use Should Continue: Minister
  March 6, 2024

• Opdivo Faces 15% Slash in Spillover, Re-Pricing to Hit 23 Drugs in FY2024 Revision
  March 5, 2024

• Drug Prices Cut by 4.67% in FY2024 Revision, 314 APIs to Keep Full Prices with PMP
  March 5, 2024

• Shionogi’s COVID Pill Xocova Lands Standard Approval in Japan
  March 5, 2024

• Japan Panel Clears Astellas’ Gastric Cancer Med for Approval after FDA Rejection
  March 5, 2024

• MHLW to Ask All Generic Makers in Japan to Execute Self-Inspections
  March 4, 2024

• Japan’s Revised Drug Distribution Guidelines Take Effect
  March 4, 2024

• PMDA Reviewing Safety Risks for 4 CAR-T Therapies and More
  March 4, 2024

• Generic Mergers, Product Consolidations Unlikely to Pose Antitrust Issue: FTC Official
  March 1, 2024

• Chugai’s PNH Med, Takeda’s cTTP Therapy Now in Line for Japan Approval
  March 1, 2024

• Hospitals, Pharmacies Must Also Join Effort in Improving Drug Distribution: Expert Panel Member
  February 29, 2024

• MHLW Sets Out to Beef Up Inspector Skills with Nationwide Sharing of GMP Reports
  February 29, 2024

• Health Minister Reaffirms April Start of New Drug Shortage Reporting Scheme
  February 28, 2024

• MHLW Panel Endorses Lowe Syndrome as Designated Intractable Disease
  February 28, 2024

• NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
  February 27, 2024

• Show Change in Development Trends before Seeking 2026 Reform: MHLW to Pharma
  February 27, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 54
• 55
• 56
• 57
• 58
• 59
• 60
• 61
• 62
• …
• Next ›
• 最終 »